Q2 2026 Travere Therapeutics Inc Earnings Call Transcript
Key Points
- Record FILSPARI demand with over 2,000 new patient start forms across IgA nephropathy and FSGS, and record US revenue of more than $141 million for the quarter.
- Successful early adoption of FILSPARI in FSGS exceeded high expectations, with all fundamentals regarding demand, payer access, fulfillment, and revenue exceeding metrics seen during the initial phase of the IgA nephropathy launch.
- Continued growth in IgA nephropathy demand despite additional market entrants, reinforcing FILSPARI's established and differentiated positioning as the most widely utilized treatment option approved for the condition.
- The USPTO issued a Notice of Allowance for a US patent application directed to certain methods of using sparsentan in IgA nephropathy, providing additional US patent coverage upon issuance.
- Closed an exclusive licensing agreement with Everest Medicines for civorebrutinib, adding a differentiated upstream immune modulating approach to the rare kidney disease portfolio with potential application across multiple immune-mediated kidney diseases.
- Strengthened the balance sheet through successful convertible note transactions, ending the quarter with approximately $489.2 million in cash, cash equivalents, and marketable securities.
- Pegtibatinase Phase III HARMONY study enrollment is continuing, with top line results expected in the second half of 2027, positioning it as a potential first and only disease-modifying therapy for classical homocystinuria.
- Gross-to-net discounts for FILSPARI are expected to be slightly higher in the third and fourth quarters due to more FSGS patients initiating therapy with higher CMS utilization.
- The company recognized a $40 million inducement expense related to the repurchases of 2029 convertible notes during the quarter, impacting total other expense net.
- It is still early in the FSGS launch, and the company cautions against extrapolating from a single quarter, with potential seasonal impact during the summer months expected to cause some quarter-to-quarter variability in patient starts.
- The company paid a $112.5 million upfront amount to Everest Medicines following the close of the civorebrutinib transaction, which is a significant cash outflow.
- There is ongoing uncertainty regarding payer pushback on combining FILSPARI with other branded agents like APRIL inhibitors, as physicians express angst about using multiple therapies to achieve treatment targets.
- The company has not yet provided an update on the FSGS method of use patent, with patent prosecution still ongoing and no specific timeline for resolution.
Good morning, and welcome to Travere Therapeutics second quarter 2026 financial results conference call. Today's call is being recorded.
At this time, I would like to turn the conference over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.
Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' second quarter 2026 financial results and corporate update call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer.
Eric will be joined in the prepared remarks by Peter Heerma, our Chief Commercial Officer; Dr. Jula Inrig, our Head of R&D and Chief Medical Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A. Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
